- Email: [email protected]
5597835 Acyl C
PATENT ABSTRACTS
5597725 CADHERIN-SPECIFIC ANTIBODIES AND H Y B R I D O M A CELL LINES Suzuki Shintaro Torrance, CA, UNITED STATES Assigned to Doheny Eye Institute DNA sequences encoding novel cadherins, desginated cadherins-4 through - 12, are disclosed along with methods and materials for the recombinant production of the same. Antibody substances specific for the novel cadherins and cadherin peptides are disclosed as useful for modulating the natural binding and/or regulatory activities of the cadherins.
785
A composition is disclosed for use in reducing the availability of undesired lipids, such as cholesterol, in the fluid media of the gastrointestinal tract prior to absorption of the lipids across the cells lining the tract. The composition is a nontoxic, substantially nondigestible polymer to which ligands are chemically bonded through biologically stable ether groups. The ligands scavenge the undesired hpids from the fluid media.
5597835
ACYL C Assigned to Korea Institute of Science and Technology
5597802 M E T H O D OF F O R M U L A T I N G IGF-I WITH GROWTH HORMONE Clark Ross G; Yeung Douglas A; Oeswein James Q Pacifica, CA, UNITED STATES Assigned to Genentech Inc A formulation for IGF-I is disclosed that is useful in treating hyperglycemic disorders and, in combination with growth hormone, in enhancing growth of a mammal. Also disclosed is a process for preparing a formulation of growth hormone and IGF-I from the IGF-I formulation. The IGF-I formulation comprises about 2-20 mg/ml of IGF-I, about 2-50 mg/ml of an osmolyte, about !-15 mg/ml of a stabihzer, and a buffered solution at about pH 5-5.5, optionally with a surfactant.
5599535 METHODS FOR THE CYTO-PROTECTION OF THE TRABECULAR M E S H W O R K Polansky Jon R; Bloom Ernest; Fauss Donald J Mill Valley, CA, UNITED STATES Assigned to Regents of the University of California
5597810 M E T H O D FOR REDUCING ABSORPTION OF UNDESIRED LIPIDS IN THE GASTROINTESTINAL TRACT Hoffman Allan; Choi N S UNITED STATES
A novel ACAT inhibitor of formula (I) useful for the treatment of hyperlipidemia produced from AspergiUus fumigatus FM-F-37; derivatives of said ACAT inhibitor, which are separated from the culture of A. fumigatus FM-F-37 or prepared by a chemical process, also possess ACAT inhibition property. (*See Patent for Chemical Structure*) (I).
Seattle, WA,
The invention concerns the recognition that certain non-steroidal anti-inflammatory agents produce cytoprotective effects on trabecular cells, and thus can be used to prevent injury to the cells and treat the loss of trabecular cells caused by oxidative or other forms of injury to the cells. Such treatment can ameliorate the severity, or prevent, glaucoma.
5597725 CADHERIN-SPECIFIC ANTIBODIES AND H Y B R I D O M A CELL LINES Suzuki Shintaro Torrance, CA, UNITED STATES Assigned to Doheny Eye Institute DNA sequences encoding novel cadherins, desginated cadherins-4 through - 12, are disclosed along with methods and materials for the recombinant production of the same. Antibody substances specific for the novel cadherins and cadherin peptides are disclosed as useful for modulating the natural binding and/or regulatory activities of the cadherins.
785
A composition is disclosed for use in reducing the availability of undesired lipids, such as cholesterol, in the fluid media of the gastrointestinal tract prior to absorption of the lipids across the cells lining the tract. The composition is a nontoxic, substantially nondigestible polymer to which ligands are chemically bonded through biologically stable ether groups. The ligands scavenge the undesired hpids from the fluid media.
5597835
ACYL C Assigned to Korea Institute of Science and Technology
5597802 M E T H O D OF F O R M U L A T I N G IGF-I WITH GROWTH HORMONE Clark Ross G; Yeung Douglas A; Oeswein James Q Pacifica, CA, UNITED STATES Assigned to Genentech Inc A formulation for IGF-I is disclosed that is useful in treating hyperglycemic disorders and, in combination with growth hormone, in enhancing growth of a mammal. Also disclosed is a process for preparing a formulation of growth hormone and IGF-I from the IGF-I formulation. The IGF-I formulation comprises about 2-20 mg/ml of IGF-I, about 2-50 mg/ml of an osmolyte, about !-15 mg/ml of a stabihzer, and a buffered solution at about pH 5-5.5, optionally with a surfactant.
5599535 METHODS FOR THE CYTO-PROTECTION OF THE TRABECULAR M E S H W O R K Polansky Jon R; Bloom Ernest; Fauss Donald J Mill Valley, CA, UNITED STATES Assigned to Regents of the University of California
5597810 M E T H O D FOR REDUCING ABSORPTION OF UNDESIRED LIPIDS IN THE GASTROINTESTINAL TRACT Hoffman Allan; Choi N S UNITED STATES
A novel ACAT inhibitor of formula (I) useful for the treatment of hyperlipidemia produced from AspergiUus fumigatus FM-F-37; derivatives of said ACAT inhibitor, which are separated from the culture of A. fumigatus FM-F-37 or prepared by a chemical process, also possess ACAT inhibition property. (*See Patent for Chemical Structure*) (I).
Seattle, WA,
The invention concerns the recognition that certain non-steroidal anti-inflammatory agents produce cytoprotective effects on trabecular cells, and thus can be used to prevent injury to the cells and treat the loss of trabecular cells caused by oxidative or other forms of injury to the cells. Such treatment can ameliorate the severity, or prevent, glaucoma.